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per hospital is 105 with 81% among three models: Abbott Life-
care 4100 PCA Plus II, Baxter Health care PCA II, and Baxter
Ipump Pain Management System. Average pump life is 7.7 years.
Sixty-nine percent of hospitals use only one pump model.
Approximately 92% of hospitals own most (93%) of their
pumps. The mean and median pump utilization rates are 68%
and 78%, respectively (n = 9 hospitals). Fifty-four percent of hos-
pitals use both pre-ﬁlled reservoirs (PFR) and staff-ﬁlled reser-
voirs (SFR); 31% use only SFR, and 15% use only PFR. For PFR,
69% of hospitals use morphine, 54% use meperidine, 23% use
hydromorphone, and 8% use fentanyl. For SFR, 77% use hydro-
morphone, 39% use fentanyl, 31% use morphine, and 15% use
meperidine. Hospitals store pumps in multiple locations, with
77% storing them in nursing units, 69% in recovery rooms, 54%
in central supply, 23% in operating rooms, and 15% in phar-
macies, adding to the complexity of IV PCA management. Reser-
voirs also are stored in multiple locations, with 100% of
hospitals storing them in nursing units, 85% in recovery rooms,
31% in operating rooms, and 23% in satellite pharmacies.
Transportation of pump and analgesia from storage to patient
takes approximately 5.7 and 7.6 minutes, respectively. CON-
CLUSIONS: The results of this interim analysis suggest hospital
IV PCA pump logistics vary widely and may signiﬁcantly affect
economics of IV PCA.
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Drugs containing Acetaminophen as a single active ingredient are
included in the list of over-the-counter (OTC) drugs allowed to
be sold in non-pharmacy stores in Israel beginning mid-2005. In
an event of severe overdose, Acetaminophen may cause severe
liver damage, which may result death if not treated urgently.
OBJECTIVE: 1) To examine the knowledge and perception of
parents to children and adolescents regarding the safety, adverse
effects and toxicity of Acetaminophen OTC preparations; and
2)To compare this knowledge to scientiﬁc facts from medical lit-
erature and the experience of leading pediatricians and clinical
pharmacologists. METHODS: 1) Interviews of four leading
Pediatricians/Clinical pharmacologists; and 2) A survey of 193
parents, which took place in three emergency pediatric clinics of
“Maccabi Healthcare Services” (HMO) in central Israel and
among non-medical headquarters staff. The answers were
processed using statistical software. Inﬂuences of several demo-
graphic factors on parents’ answers were examined. RESULTS:
In total, 65% of the enrolled parents had the perception that
non-prescription drugs might be harmful if not used properly,
while 55% of them thought that Acetaminophen might be
harmful if not used properly. In the higher education group more
parents thought that Acetaminophen had had adverse effects.
Higher proportion of parents of two or more children felt they
had knew how to use Acetaminophen brands properly compared
to parents of one child. More than 60% of the parents reported
that they usually purchase Acetaminophen brands without a pre-
scription. About 80% read the patient’s insert. CONCLUSIONS:
Enrolled parents perceive Acetaminophen brands to be safer than
the average non-prescription drug, even though it is known that
in an event of over-dosage Acetaminophen is more toxic than
most other non-prescription drugs. More educated parents in the
survey sample were more aware of the dangers of improper use
of Acetaminophen.
PPN5
TYPES OF PROBLEMS ASSOCIATED WITH INTRAVENOUS
PATIENT-CONTROLLED ANALGESIA (IV PCA) INFUSION
PUMPS:AN ANALYSIS OF THE MANUFACTURER AND USER
FACILITY DEVICE EXPERIENCE (MAUDE) DATABASE
Hankin C1, Zhang M2
1BioMedEcon, LLC, San Jose, CA, USA; 2Ortho McNeil
Pharmaceutical, Inc, Raritan, NJ, USA
OBJECTIVES: Although isolated case reports have documented
operator programming errors associated with intravenous
patient-controlled analgesia (IV PCA) infusion pumps, no sys-
tematic analysis of IV PCA-associated problems has been per-
formed. The objective of this study was to use the Manufacturer
and User Facility Device Experience (MAUDE) database, a large
publicly available database maintained by the US Food and Drug
Administration (FDA), to characterize the types of problems
associated with the use of IV PCA infusion pumps. METHODS:
We extracted all IV PCA-related MAUDE case reports from
January, 2002 through December, 2003. Reported causes of
events were abstracted and classiﬁed as: possible operator errors
(eg, pump programming errors); possible patient-related events
(eg, patient tampering), possible device-related events (eg, device
malfunctions), possible adverse drug reactions, and indetermi-
nate events (unspeciﬁed causes). RESULTS: We found 2009
unique IV PCA-related reported events. Number of events
increased from 455 in 2002 to 1554 in 2003, although the FDA
instituted no corresponding changes in reporting requirements
or data collection during these two years. Among all IV PCA-
related reports, 79.1% (N = 1590) were possible device-related
events, 6.5% (N = 131) were possible operator errors, 1.2% (N
= 25) possible adverse drug reactions, 0.6% (N = 12) possible
patient-related events, and 12.6% (N = 251) were indeterminate
events. The device manufacturer conﬁrmed 61% of the reported
possible device-related events. CONCLUSIONS: Previously pub-
lished single case reports of problems with IV PCA infusion
pumps highlight operator error. Our analysis of the MAUDE
data suggests, however, that nearly 80% of reported problems
were attributable to possible device-related events. Although
reporting bias may contribute to the high rates of possible device-
related events (ie, operator errors may be reported as device-
related events), more than half of the possible device-related
malfunctions were conﬁrmed upon manufacturer inspection. To
our knowledge, this is the ﬁrst study to use a large, retrospective
database to examine IV PCA-related problems.
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OBJECTIVES: Dose increases during long-term therapy with
strong opioids have often been reported and result from deteri-
oration of the primary disease or from tolerance development.
The purpose of this study was to compare drug utilization 
patterns with regard to dose changes of transdermal (TD) fen-
tanyl and TD buprenorphine in cancer and non-cancer patients.
METHODS: Retrospective analysis of the “IMS Disease 
Analyzer—mediplus” database which provided data from 400
general practices in Germany. An evaluation according to a pre-
vious peer-reviewed study showed that patients on long-term
treatment (three months and longer) with TD fentanyl or TD
buprenorphine had received similar analgesic pre-medication
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and could be considered identical cohorts with similar pain
intensity. For the evaluation of dose developments mean daily
dosages of the ﬁrst and last prescribed patches were calculated
and compared. RESULTS: In all patients, the prescribed mean
daily doses increased during therapy. However, this increase 
was more pronounced in patients on TD fentanyl treatment. 
The mean percentile intra-individual increases per day in cancer
patients were up to 0.42% and 0.17% in the TD fentanyl and
TD buprenorphine patients, respectively, and in non-cancer
patients to 0.25% for TD fentanyl and 0.09% for TD buprenor-
phine. The higher dose increase in TD fentanyl patients was 
statistically signiﬁcant (p < 0.0001) and could not be explained
by co-medication or titration. CONCLUSIONS: The analyses
were conducted on identical cohort patients with similar pain
intensity, expecting similar drug utilization patterns for TD
buprenorphine and TD fentanyl. The lower increase of the mean
daily doses in TD buprenorphine patients suggests a higher 
tolerance development with TD fentanyl compared to TD
buprenorphine.
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OBJECTIVE: To determine the factor structure of the Beck
Depression Inventory (BDI) in a chronic pain population. The
factor structure will be discussed in the context of assessing
depression in pain. METHODS: The BDI was administered to a
convenience sample of 128 patients who had experienced pain
for a duration of at least three-months. The BDI is a 21 item
instrument; however, for the purposes of this study one item
assessing suicidal ideation was deleted. Conﬁrmatory factor
analysis using maximum likelihood estimation techniques were
run for several published factor structures of the BDI that have
been evaluated in pain patients. RESULTS: The average score on
the BDI for this sample was 20.54 (s.d. = 8.8). Based on a single
factor score, 25% (n = 32), 23.4% (n = 30), 14.1% (n = 18) and
1.6% (n = 2) of the sample was classiﬁed with borderline clini-
cal depression, moderate depression, severe depression, and
extreme depression respectively. Results from the factor analysis
suggest that various two and three factor solutions provide 
adequate ﬁt to the data. A two factor solution comprising items
that reﬂect negative view of the self and impaired physical func-
tion provided best ﬁt to the data. The chi-square statistic calcu-
lated for this model was 75.45 based on 64 degrees of freedom
(p = 0.15). Patients provided low scores on the negative view 
of self factor (mean = 4.39, s.d. = 3.65) and high scores on the
impaired physical function factor (mean = 9.12, s.d. = 3.44).
CONCLUSION: Pain has a signiﬁcant negative impact on a
variety of functions. However, pain patients do not exhibit the
cognitive biases displayed by patients diagnosed with major
depressive disorder.
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OBJECTIVES: Measuring back pain for further clinical research
required the linguistic validation of a nine-item questionnaire
developed in US English. Based on the assumption that the orig-
inal concepts were universally appropriate, we aimed to develop
language versions of a US back pain questionnaire according to
a rigorous methodology to ensure the conceptual equivalence
between the original and the translations. METHODS: The
process was conducted by a specialist in each target country
using the following standardized methodology: 1) two forward
translations by professional translators, native speakers of the
target language and ﬂuent in English; 2) comparison and recon-
ciliation of the translations by the specialist in the target country
and the translators; 3) backward translation by a native English
speaker; 4) comparison of source and backward version; and 5)
comprehension test on ﬁve individuals suffering from back pain
and review by one clinician. RESULTS: Issues regarding the uni-
versal appropriateness of the original concepts emerged during
the creation of the 35 language versions. Items investigating the
respondent’s ability to get in and out of his car had to be refor-
mulated in countries where the ownership of cars was rare. 
Similarly for countries in which people did not wear socks or
stockings an alternative question had to be found. CONCLU-
SION: The 35 language versions were established according 
to a rigorous translation methodology. The process ensured 
the conceptual equivalence of all language versions to facilitate
the international comparison and pooling of data. This process
also reveals that the original concepts are not necessarily uni-
versally appropriate. This indicates the necessity to integrate
international feedback on concepts before the original question-
naire is ﬁnalized to facilitate the cross-cultural equivalence of
concepts.
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OBJECTIVE: Pain in persons at the end of life has not yet been
well described. The purpose of this study is to describe the occur-
rence of severe pain among persons who received hospice care
in the US. METHODS: Data for this study were derived from a
database developed by excelleRx Incorporated, which provides
pharmacy services to US hospices. The excelleRx database
includes demographic and clinical data for persons during the
period from February 1, 2000—July 26, 2004. Worst pain inten-
sity during the previous 24 hours is assessed using a zero—ten
numeric rating scale (NRS; zero = none, ten = worst) by hospice
nurses periodically during a person’s hospice admission.
RESULTS: Of 326,737 persons who received hospice care in 419
US hospices during the study period, severe pain (NRS
seven–ten) was reported at least once by 20.3% of persons with
at least one pain score. Of these individuals, mean age of persons
who died during hospice care was 68.9 years (median 70.7, SD
14.4), median length of service was 42.0 days, 53.7% were
female, 78.0% were Caucasian, 7.4% were cared for in LTC hos-
pices, and 73.9% had a primary diagnosis of cancer. Within the
subset of persons who reported severe pain and were treated in
a long-term-care hospice, 66.8% were female, 78.1% were Cau-
casian, and 47.6% had a primary diagnosis of cancer. CON-
CLUSION: Severe pain was reported at least once by a
substantial percentage of persons in this cohort, of those indi-
viduals cared for in long-term-care facilities, and of persons with
a primary diagnosis of cancer. These data provide insight into
improving the care of persons at the end of life.
